31 January 1996 9-acetoxy-2,7,12,17-tetrakis-(B-methoxyethyl)- porphycene (ATMPn): a novel photosensitizer for photodynamic therapy--intracellular uptake and distribution in vitro
Author Affiliations +
Abstract
Photodynamic therapy (PDT) in dermatology is of growing interest and there are efforts to develop new sensitizers for topical application. In vitro parameters for photodynamic therapy with 9-acetoxy-2,7,12,17-tetrakis-((beta) -methoxyethyl)-porphycene (ATMPn) using two human skin derived cell lines (HaCaT keratinocytes and dermal fibroblasts) were established. Short time flow cytometry analysis (0-2,000 s) for both cell lines revealed an immediate increase of intracellular ATMPn-fluorescence after start of incubation (100 (mu) g/ml). Long time flow cytometry analysis (0-24h) in both cell lines showed a constant increase of fluorescence up to 12h, with a steady-state up to 24h. Confocal laser scan microscopy showed spotty, granular fluorescence inside the cytoplasm after different incubation times, similar to the pattern of rhodamine dye which stains mitochondria. However, uptake of ATMPn in fibroblasts was slower than in keratinocytes. These results confirm the rapid intracellular uptake of ATMPn in vitro and indicate there is a sufficient photodynamic effect when ATMPn-sensitized cells are exposed to light.
© (1996) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Rolf-Markus Szeimies, Sigrid Karrer, Pia Steinbach, Helmut Messmann, Michael Landthaler, "9-acetoxy-2,7,12,17-tetrakis-(B-methoxyethyl)- porphycene (ATMPn): a novel photosensitizer for photodynamic therapy--intracellular uptake and distribution in vitro", Proc. SPIE 2625, Photochemotherapy: Photodynamic Therapy and Other Modalities, (31 January 1996); doi: 10.1117/12.230953; https://doi.org/10.1117/12.230953
PROCEEDINGS
4 PAGES


SHARE
KEYWORDS
Luminescence

Photodynamic therapy

In vitro testing

Skin

Flow cytometry

Confocal microscopy

Rhodamine

Back to Top